SYDNEY--(BUSINESS WIRE)--AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced $18M in Australian Federal Government Funding from the ...

Radiopharmaceutical company AdvanCell has received $18 million from the Medical Research Future Fund (MRFF) to develop and deliver targeted alpha therapies for prostate cancer, which is the second ...

In other radiopharmaceuticals news, Sydney, Australia-based AdvanCell announced in February 2025 that it had successfully completed an oversubscribed, $112 million round of Series C financing (2). The ...

AusBiotech's Medtech Invest 2025, Australia's premier medical technology investment conference, opens today in Sydney — kicking off a ...

While biotech and medtech startups dominated total capital raised — buoyed by a $179 million raise by Harrison.ai and a $178.6 million round for cancer treatment startup AdvanCell — AI edged ...

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology ...

Cancer treatment start-up AdvanCell’s raised $171 million and Aravax raised $66 million to help grow its allergy symptom reduction products. The average deal size rose to an all-time high over ...

Eli Lilly and Company (NYSE:LLY) tops our list for being one of the best pharmaceutical stocks. It develops, manufactures, discovers, and sells pharmaceutical products. These goods cover ...

Other companies are looking at lead-212 RLTs, meanwhile, including ARTBIO and POINT Biopharma/AdvanCell, but Orano Med is thought to be in the lead in the category. Sanofi's chief executive Paul ...